top of page

Renren Bai / 白仁仁

 

Ph.D., Associate Professor,

School of Pharmaceutical Sciences，Zhejiang University of Technology

 

Personal Homepage:

      http://www.zjutyxy.zjut.edu.cn/frontend/showNews.html?hashcode=333345300

Emory University Personal Homepage:       

      https://brainimaging.emory.edu/member/rbai/

Google Scholar: https://scholar.google.com.hk/citations?user=UycdgQwAAAAJ&hl=zh-CN&oi=ao

ResearchGate:    https://www.researchgate.net/profile/Renren_Bai​

Email:   renrenbai@zjut.edu.cn     renren.bai@emory.edu        

 

Biosketch

 

Dr. Renren Bai joined School of Pharmaceutical Sciences at Zhejiang University of Technology in 2017. Dr. Bai holds a BS in Pharmaceutical Engineering and a PhD in Medicinal Chemistry from China Pharmaceutical University. He followed these with a postdoctoral training appointment at the Emory University School of Medicine for three years, first in Department of Radiology and Imaging Science and later in Department of Radiation Oncology. He had more than seven years’ research experience in antitumor and anti-cardiovascular drug development and acquired a diverse range of skills in natural products modification and drug discovery. He published 15 journal papers in European Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters during the past years.

 

 

Education

2017.08 -                Associate professor, School of Pharmaceutical Sciences, Zhejiang University of Technology,                                    Hangzhou,  China

2014.08 - 2018.02  Post-doc, Emory University, School of Medicine, Atlanta, GA, USA
2008.09 - 2013.06  M.S.&Ph.D., Medicinal Chemistry, China Pharmaceutical University, Nanjing, China 
2004.09 - 2008.06  B. S., Pharmaceutical Engineering, China Pharmaceutical  University, Nanjing, China 

 

 

Research

CXC Chemokine Receptor 4 (CXCR4) plays important roles in pathological processes, such as cancer metastasis, tumor angiogenesis, cell trafficking in autoimmune diseases and inflammatory conditions.

 

The compounds designed by Dr. Bai are partial antagonists of CXCR4, blocking inflammation and cancer metastasis without mobilizing stem cells. Therefore, our compounds have a great potential therapeutic use for a long-term use without unintended side effect due to stem cell mobilization. In order to shorten the drug development cycle, especially in the stage of lead compound optimization, Computer Aided Drug Design (CADD) has been adapted for virtual drug screening of thousands of compounds. After developing the promising CXCR4 inhibitory structural skeleton by rational design based on the previous experience, a self-designed system is used to prepare virtual libraries of thousands of compounds that are commercially available. By evaluating these compounds by virtual screening, we can identify several promising lead compounds, which can be further developed as drug candidates in an accelerated fashion.

 

Reviewer

Analytical Methods

Biomolecules

Chinese Journal of Natural Medicines

Current Organic Synthesis

Drug, Healthcare and Patient Safety

European Journal of Medicinal Chemistry

Journal of Pain Research

Marine Drugs

Molecules

Medicinal Chemistry

Nutrients

 

 

Publications

  1. Renren Bai*, Jian Sun, Zhongxing Liang, Younghyoun Yoon, Eric Salgado, Amber Feng, Yoonhyeun Oum, Yuanyuan Xie, Hyunsuk Shim*. Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives. European Journal of Medicinal Chemistry. 2018, 150, 195-205. 

  2. Renren Bai, Zhongxing Liang, Younghyoun Yoon, Eric Salgado, Amber Feng, Saumya Gurbani, Hyunsuk Shim*. Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study. European Journal of Medicinal Chemistry. 2017, 136, 360-371. 

  3. Renren Bai, Qi Shi, Zhongxing Liang, Younghyoun Yoon, Shuangping Liu, Hyunsuk Shim*. Development of new CXCR4 modulators by virtual high throughput screening of a novel amide-sulfamide compound library. European Journal of Medicinal Chemistry. 2017, 126, 464-475.

  4. Renren Bai, Zhongxing Liang, Younghyoun Yoon, Shuangping Liu, Theresa Gaines, Yoonhyeun Oum, Qi Shi, Suazette Reid Mooring, Hyunsuk Shim*. Symmetrical bis-tertiary amines as novel CXCR4 inhibitors. European Journal of Medicinal Chemistry. 2016, 118, 340-350. 

  5. Renren Bai, Xiaojing Huang, Xue Yang, Wen Hong, Yiqun Tang, Hequan Yao, Jieyun Jiang, Jie Liu*, Mingqin Shen, Xiaoming Wu*, Jinyi Xu*. Novel hybrids of natural isochroman-4-one bearing N-substituted isopropanolamine as potential antihypertensive candidates. Bioorganic & Medicinal Chemistry. 2013, 21, 2495-2502.

  6. Renren Bai, Zhen Wei, Jie Liu, Weijia Xie, Hequan Yao, Xiaoming Wu*, Jieyun Jiang, Qiujuan Wang, Jinyi Xu*. Synthesis and biological evaluation of 4′-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists. Bioorganic & Medicinal Chemistry. 2012, 20, 4661-4667.

  7. Renren Bai, Xue Yang, Yao Zhu, Jie Liu*, Mingqin Shen, Xiaoming Wu, Jinyi Xu*. Novel nitric oxide-releasing isochroman-4-one derivatives: Synthesis and evaluation of antihypertensive activity. Bioorganic & Medicinal Chemistry. 2012, 20, 6848-6855.

  8. Renren Bai, Jie Liu, Yao Zhu, Xue Yang, Chen Yang, Lingyi Kong, Xiaobing Wang, Hengyuan Zhang, Hequan Yao, Mingqin Shen, Xiaoming Wu*, Jinyi Xu*. Chiral separation, configurational identification and antihypertensive evaluation of (±)-7,8-dihydroxy-3-methyl-isochromanone-4. Bioorganic & Medicinal Chemistry Letters. 2012, 22, 6490-6493.

  9. Ren-Ren BAI, Jin-Yi XU, Xiao-Ming WU. Current natural products with antihypertensive activity. Chinese Journal of Natural Medicines. 2015, 13, 721–729.

  10. Ren-Ren BAI, Sheng-Tao XU, Jie LIU, Wen HONG, Yi-Qun TANG, Xiao-Ming WU, Wei-Jia XIE*, He-Quan YAO, Jin-Yi XU*. Synthesis and β-adrenergic blocking activity of oxime ether hybrids derived from a natural isochroman-4-one. Chinese Journal of Natural Medicines. 2013, 11, 538–545.

  11. Renren Bai*, Xiaokang Jie, Eric Salgado, Jian Sun, Yao Zhu, Thomas Pickel, Yuanyuan Xie, Jichao Chen, Jinyi Xu*. Rational Design, Synthesis and Biological Evaluation of Novel Derivatives Based on In Vivo Metabolism of Natural Product beta-elemene. Letters in Drug Design & Discovery. 2018, 15(8), 905-912.

  12. Theresa Gaines, Davita Camp, Renren Bai, Zhongxing Liang, Younghyoun Yoon, Hyunsuk Shim*, Suazette Reid Mooring*. Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors. Bioorganic & Medicinal Chemistry. 2016, 24, 5052-5060.

  13. Jichao Chen, Wenli Duan, Renren Bai，Hequan Yao, Jing Shang*, Jinyi Xu*. Design, synthesis and antioxidant activity evaluation of novel β-elemene derivatives. Bioorganic & Medicinal Chemistry Letters. 2014, 24, 3407-3411.

  14. Ji-Chao CHEN, Wen-Li DUAN, Ren-Ren BAI， He-Quan YAO, Xiao-Ming WU *, Jing SHANG *, Jin-Yi XU *. Synthesis of 13-β-elemene ester derivatives and evaluation of their antioxidant activity in human umbilical vein endothelial cells. Chinese Journal of Natural Medicines. 2015, 13, 618–627.

  15. Jie Liu, Hao Ren, Jinyi Xu*, Renren Bai, Qi Yan, Wenlong Huang, Xiaoming Wu*, Jihua Fu, Qiujuan Wang, Qian Wu, Rong Fu. Total synthesis and antihypertensive activity of (±)-7,8-dihydroxy-3-methyl-isochromanone-4. Bioorganic & Medicinal Chemistry Letters. 2009, 19, 1822–1824.

  16. Jie Liu, Qin Liu, Xue Yang, Shengtao Xu, Hengyuan Zhang, Renren Bai, Hequan Yao*, Jieyun Jiang, Mingqin Shen, Xiaoming Wu, Jinyi Xu*. Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates. Bioorganic & Medicinal Chemistry, 2013, 21, 7742-7751.

  17. Pingping Li, Jian Sun, Xiaohe Xu, Zhisheng Mi, Yuyan Lin, Jingya Cheng, RenrenBai, Yuanyuan Xie*. Ferric nitrate-promoted oxidative esterification of toluene with N-hydroxyphthalimide: Synthesis of N-hydroxyimide esters. Tetrahedron Letters. 2018, 59(27), 2640-2643.

  18. YiyanYan, Xiaohe Xu, Xiaokang Jie, Jingya Cheng, Renren Bai, Qi Shuai, Yuanyuan Xie*. Selective and facile synthesis of α, β-unsaturated nitriles and amides with N-hydroxyphthalimide as the nitrogen source. Tetrahedron Letters. 2018, 59(29), 2793-2796.

  19. Jun Xu, Ke Cheng, Chao Shen, Renren Bai, Yuanyuan Xie*, Pengfei Zhang*. Coordinating Activation Strategy-Induced Selective C-H Trifluoromethylation of Anilines.  ChemCatChem. 2018, 10(5), 965-970.

  20. Xiaohe Xu, Jian Sun, Yuyan Lin, Jingya Cheng, Pingping Li, Xiaoying Jiang, Renren Bai, Yuanyuan Xie*. Iron-Nitrate-Catalyzed Oxidative Esterification of Aldehydes and Alcohols with N-Hydroxyphthalimide: Efficient Synthesis of N-Hydroxyimide Esters. European Journal of Organic Chemistry. 2017, 47, 7160-7166.

 

 

Literatures

  1. Jinyi Xu, Renren Bai, Xiaoming Wu. Progress in the research of novel drugs using angiotensin II recepter as a target [M]. Progress in Medicinal Chemistry. Beijing, Chemistry Industry Press, 2011, 51-79.

  2. Jinyi Xu, Renren Bai, Xiaoming Wu. Advance in the research of cardiovascular medicine in china from 2007 to 2009 [M]. Chinese Pharmaceutical Yearbook. Shanghai, Second Military Medical University Press, 2010, 23-30.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

bottom of page